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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by the loss of
dopamine (DA) neurons in the substantia nigra. The most effective treatment is DA replacement
therapy using the DA precursor L-DOPA, which can unfortunately often result in L-DOPAinduced dyskinesia (LID). Animal studies in hemi-Parkinsonian rats have shown glutamatergic
NMDA receptor antagonists to be effective in treating both PD symptoms and LID. However,
the cognitive side effects prevent these drugs from passing clinical trials. Upregulation of GLT-1,
the primary glutamate transporter that removes glutamate from the synapse, could be an
alternative to direct receptor antagonism. The β-lactam antibiotic ceftriaxone has been shown to
substantially increase GLT-1 protein expression and activity in the brain without side effects. In
Experiment 1 it was found that sub-chronic injections of 100 mg/kg ceftriaxone in unilaterally 6OHDA-lesioned rats caused a 44% increase in impaired forepaw stepping, a measure of
bradykinesia, that lasted at least 30 days after the last ceftriaxone injection. In Experiment 2, subchronic injections of 50 mg/kg ceftriaxone resulted in a 41% increase in impaired forepaw
stepping that was found to be equivalent to that produced by 10 mg/kg L-DOPA. However
unlike ceftriaxone, treatment with L-DOPA resulted in the development of L-DOPA-induced
dyskinesia. Ceftriaxone was able to slow the development of LID, but not decrease the
expression of pre-established LID. Indicating that the effects of ceftriaxone on forepaw stepping
were due to enhanced GLT-1 function, injections of the selective GLT-1 inhibitor,
dihydrokainate (DHK) reduced the improvement in stepping produced by ceftriaxone.
Collectively, these data indicate that ceftriaxone may be a superior treatment for Parkinson’s
disease than L-DOPA.
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The β-lactam antibiotic ceftriaxone as a treatment for the symptoms of Parkinson’s disease and
L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.

Parkinson’s disease (PD) is the second-most common progressive neurodegenerative
disorder, second to Alzheimer’s disease, affecting 2% of the population over 65. Parkinson’s is
characterized by the progressive loss of dopaminergic (DA) input from the substantia nigra pars
compacta to the striatum of the basal ganglia (Massie et al., 2010). Loss of striatal DA causes
five typical motor dysfunctions: akinesia, muscle rigidity, resting tremors, gait disturbances, and
postural imbalance (Cenci & Lundblad, 2006). Symptoms typically begin after the loss of 50-60%
of DA neurons and 70-80% of the striatal extracellular DA (Cenci & Lundblad, 2006).
At this point there is no cure, prevention, or slowing of Parkinson’s disease, only
symptom management. Symptoms are most commonly treated with the dopamine precursor
levodopa (L-DOPA), which remains the most effective anti-parkinsonian drug 40 years after its
development (Calon, Morissette, Raiput, Hornykiewicz, Bedard, & Di Paolo, 2003). L-DOPA
treatment causes a mild to dramatic reduction of motor deficits (Cenci & Lundblad, 2006) by
increasing the synthesis of dopamine (Carta, Carlsson, Kirik, & Bjorklund, 2007). However, as
the disease progresses, there are fewer DA neurons available to synthesize DA. Interestingly,
serotonin (5-HT) neurons are able to convert L-DOPA into DA and, as the disease progresses
and there are fewer DA neurons, these 5-HT neurons are responsible for the majority of the DA
release in the striatum (Miller & Abercrombe, 1999). Because the 5-HT neurons are less able to
regulate release, extracellular DA concentrations fluctuate depending on L-DOPA availability
(Carta et al., 2007). This sporadic activation of DA receptors can lead to reduced L-DOPA
efficacy, motor fluctuations, and, ultimately, prevalent side effects such as L-DOPA-induced
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dyskinesia (LID; Mouradian, Heuser, Baronti, & Chase, 1990). Both motor fluctuations and LID
develop in 40% of patients after 5 years and in 90% of patients after 9 years of L-DOPA
treatment (Cenci & Lundblad, 2006; Kobylecki, Cenci, Crossman, Ravenscroft, 2010). Because
of these undesirable side effects to the primary PD treatment, it is clear that better therapies are
needed.
Recently it has become widely accepted that the pathophysiology of PD and LID also
involves increased glutamatergic transmission within the striatum. With the loss of dopaminergic
projections onto glutamatergic corticostriatal afferents, these striatal inputs are disinhibited,
causing an increased release of glutamate into the striatum (Nash et al., 2000; Chung, Chen,
Chan, &Yung, 2008). Moreover, this glutamate release appears to be further enhanced during
LID (Jonkers et al., 2002; Robelet et al., 2004). Indicating the causal nature of increased
glutmate in PD, antagonists, especially of the NMDA receptor, have been shown to improve PDlike motor symptoms (Kelsey, Maque, Pijanowski, Harris, Kleckner, & Matthews, 2004; Nash et
al., 2000), potentiate L-DOPA’s therapeutic effects (Kelsey et al., 2004; Klockgether & Turski,
1990), and suppress LID in animal models (Blanchet, Konitsiotis, & Chase, 1998; Kobylecki et
al., 2010). Although NMDA antagonists have shown therapeutic effects in human PD patients
(Snow, Macdonald, Mcauley, & Wallis, 2000), they have a very narrow therapeutic index
(Metman, Blanchet, Munckhof, Dotto, Natte, & Chase, 1998). Moreover, most NMDA receptor
antagonists have failed clinical trials due to intolerable side effects, suggesting the need for
alternative therapies (Chu et al., 2007).
More recently, upregulation of the primary glutamate transporter GLT-1 (EAAT-2 in
humans) is being explored as an alternative to direct glutamate antagonism in many
neurodegenerative diseases other than PD. In 2005 Rothstein et al. discovered that β-lactam
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antibiotics, such as ceftriaxone, increase GLT-1 protein expression by 300-600% (Rothstein et
al., 2005) and decrease extracellular glutamate by 50% (Rasmussen, Baron, Kim, Unterwald, &
Rawls, 2011). Thus, far ceftriaxone has proven useful in reducing neurodegeneration and
behavioral deficits in animal models of amyltrophic lateral sclerosis (ALS), stroke, and
Huntington’s disease (Miller et al., 2008; Rothstein et al., 2005; Thone-Reineke et al., 2008)
Conveniently, the dose of ceftriaxone required to upregulate GLT-1 protein expression to a level
that is neuroprotective falls within the range approved by the FDA to treat meningitis (Nau et al.,
1993; Rothstein et al., 2005).
In this study I will test the hypothesis that the upregulation of GLT-1 by ceftriaxone will
also improve Parkinson-like symptoms and decrease LID in the 6-OHDA-lesioned hemiparkinsonian rat. In this introduction, I will first examine the pathophysiology of PD and LID. I
will then focus on the role of glutamate. I will finish by exploring the actions of ceftriaxone in
other neurodegenerative disorders as a background for its use in the treatment of PD and LID.
Parkinson’s Disease
Typically Parkinson’s disease first presents with a resting tremor in a limb on the side
contralateral to the greatest deterioration (Guttman, Kish, & Furukawa, 2003). Bradykinesia then
begins to develop, causing slowing of movement and difficulty initiating action. Rigidity of
muscles at rest, postural imbalance, and gait disturbances are also very common (Cenci &
Lundblad, 2006; Guttman, 2003). Often motor symptoms occur concurrently with non-motor
symptoms, whose etiology is less understood. These typically include REM sleep disorder and
autonomic dysfunction (Braak, Del Tredici, Rub, de Vos, Steur, & Braak, 2003). In the later
stages of the disease some patients develop dementia (Braak et al., 2003). However, no two
patients are alike in the type or progression of symptoms (Halliday & McCann, 2010). Diagnosis
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is typically made based on motor symptoms and response to DA replacement therapy, as there
are no specific changes associated with PD that can be detected in scans. However, a definitive
diagnosis can only be made through autopsy (Guttman et al., 2003).
Etiology and pathology of PD. The cause of Parkinson’s disease remains elusive. It is
currently thought that most cases of idiopathic PD are due to a combination of environmental
and genetic factors that cause a predisposition for the disease (Guttman et al., 2003). Although
the causes are typically unknown there is some understanding of the mechanism behind neuronal
death and disease progression. In the substantia nigra cell death is thought to be caused by a
combination of a dysfunction of the α-synuclein protein, mitochondrial dysfunction,
inflammation, oxidative stress, disruption of calcium homeostasis, and excitotoxicity caused by
excess glutamate (Duty, 2010; Greenamyre & Hastings, 2004; Schulz, 2007). A common
occurance is the aggregation of the α-synuclein protein in Lewy bodies, which are thought of as a
hallmark of the disease of both idiopathic and the less common hereditary form of the disease
(Greenamyre & Hastings, 2004). α-synuclein proteins are susceptible to environmental influence,
causing them to unfold, aggregate and form fibrils that make up the main component of Lewy
bodies (Schulz, 2007). Environmental factors typically associated with the disease include
overexposure to carbon monoxide, heavy metals, and pesticides (Guttman et al., 2003; Murdoch,
Cheer, & Wagstaff, 2004).
Basal Gangia circuitry and PD. The motor symptoms of Parkinson’s disease are caused
by the degeneration of the dopamine neurons of the substantia nigra pars compacta, which results
in the loss of striatal DA and resultant disruption in function of the basal ganglia (Massie et al.,
2010). In order to understand the changes in the basal ganglia caused by the depletion of
dopamine in the striatum, it is imperative to understand the connections and interactions between
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Figure 1a and 1b. Normal and Abnormal Function of the Basal Ganglia. In normal functioning
basal ganglia, both direct and indirect pathways coordinate input to produce refined movement.
In PD, the direct pathway has decreased input, whereas the indirect pathway becomes
overactive.
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the structures of the basal ganglia. The substantia nigra pars compacta is the major dopaminergic
afferent to the medium spiny GABAergic neurons of the striatum (Albin, Young, & Penny, 1989;
Exposito, Del Arco, Segovia, & Mora, 1999). The striatum, which is the major afferent structure
of the basal ganglia, consists of the medial caudate, containing inhibitory D2 receptors of the
indirect pathway, and lateral putamen, containing excitatory D1 receptors of the direct pathway
(Albin et al., 1989; Doig, Moss & Bolam, 2010; Feyder, Bonito-Oliva, & Fisone, 2011). In the
direct pathway, neurons from the putamen release inhibitory GABA onto the internal globus
pallidus (GPi), which decreases the release of GABA by the GPi onto the thalamic nucleus,
disinhibiting it (Castle, Aymerich, Sanchez-Escobar, Gonzalo, Obeso, & Lanciego, 2005). The
disinhibited thalamus then releases excitatory glutamate onto the motor cortex, increasing
movement (Albin et al., 1989). In contrast, activation of the indirect pathway causes inhibition of
the motor cortex, effectively opposing the direct pathway (Feyder et al., 2011). However
dopamine is inhibitory when acting on the D2 receptors of the indirect pathway, thereby
inhibiting the GABA projections from the medial caudate nucleus to the external globus pallidus
(GPe), disinhibiting it, which causes the GPe to release GABA onto the subthalamic nucleus
(STN; Albin et al., 1989; Doig et al., 2010). Inhibition of the STN reduces glutamate release onto
the GPi, preventing the GPi from inhibiting the thalamic nucleus. The disinhibited thalamic
nucleus can then excite the motor cortex, eliciting movement (Feyder et al., 2011).
In Parkinson’s disease, because of the degeneration of the dopamine neurons of the
substantia nigra, there is a decrease in dopaminergic input to both the caudate and putamen of the
striatum which decreases activity in the direct pathway (Blandini, Porter, & Greenamyre, 1996;
Feyder et al., 2011) and increases activity of the indirect pathway (Albin et al., 1989;
Klockgether & Turski, 1990), both resulting in increased activation of the STN (Nash & Brotchie,
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2002; Rylander, Recchia, Mela, Dekundy, Danysz, & Cenci, 2009) and decreased activation of
the motor cortex and, thus, decreased movement (Blandini et al., 1996; Duty, 2010).
L-DOPA
Because there is still no cure for Parkinson’s and no prevention, as its causes are
unknown, the only relief that can be brought to patients is symptom management. The most
commonly used and most effective treatment of PD symptoms is levodopa (L-DOPA), although
direct dopamine agonists are also effective (Miller & Abercrombe, 1999). L-DOPA is a
dopamine precursor that works to increase dopamine synthesis and, therefore, transmission in the
striatum (Carta et al., 2007). When L-DOPA is given to a less impaired person, the L-DOPA
easily crosses the blood-brain-barrier and is transported into dopaminergic neurons and
converted to DA by aromatic L-amino acid decarboxylase (AADC) (Miller & Abercrombe,
1999). The DA is then transported into synaptic vesicles by vesicular monoamine transporter-2
(VMAT-2; Cenci & Lundblad, 2006). Once the neuron is activated, the vesicles release the DA
into the synapse where it can either bind to DA receptors, be taken back into the DA neuron by
the high-affinity dopamine transporter (DAT), or broken down by monoamine oxidase (MAO) or
catechol-O-methyl transferase (Cenci & Lundblad, 2006; Miller & Abercrombe, 1999).
In Parkinson’s, however, because of the degeneration of the dopaminergic neurons of the
substantia nigra, there are fewer DA neurons available to take up the L-DOPA and convert it to
DA. Recent evidence suggests that serotonergic (5-HT) neurons projecting to the striatum from
the raphe nucleus also take up the excess L-DOPA. Because 5-HT cells also contain AADC and
VMAT-2, DA is able to be synthesized and released from serotonergic as well as dopaminergic
neurons into the striatum (Miller & Abercrombe, 1999). This allows L-DOPA to continue to be
therapeutic despite the degeneration of the majority of the dopaminergic neurons in the
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substantia nigra (Carta et al., 2007). Although this enhanced release of DA from 5-HT neurons
can be helpful in treating advanced cases of PD with severe DA degeneration, this release is less
effectively regulated, resulting in decreased efficacy and side effects. For example, 5-HT
neurons lack DAT, thereby decreasing the clearance of dopamine from the synapse (Cenci &
Lundblad, 2006). In addition, because serotonergic neurons lack DA autoreceptors, there is no
feedback mechanism to regulate the amount of DA being released. Finally, because the DA is
taking up room in the vesicles, there is less vesicular space available for 5-HT, leading to a
decrease in extracellular 5-HT, and, therefore, reduced activation of the serotonergic
autoreceptors further increasing extracellular DA (Carta et al., 2007). Because the DA is, thus,
released in large quantities over a short period of time, there are large fluctuations in DA release
depending on L-DOPA availability (Cenci & Lundblad, 2006). This non-physiological,
unregulated, intermittent release of DA is thought to be a major contributor to the development
of levodopa-induced dyskinesia (Carta et al., 2007; Mouradian et al., 1990). Consequently, the
application of continuous L-DOPA in patients with severe PD and LID decreases the magnitude
of LID and increases L-DOPA’s therapeutic window (Mouradian et al., 1990).
Furthermore, this unregulated, pulsatile release of large amounts of DA is almost
certainly responsible for the development of a number of motor fluctuations, most commonly
expressed as a decreased duration of effect (wearing-off) or unpredictable swings in efficacy (onoff; Hametner, Seppi, & Poewe, 2010). Wearing-off is thought to be caused by the use of all the
L-DOPA over a short period of time due to the over-release of DA by 5-HT neurons (Cenci &
Lundblad, 2006). The on-off phenomenon, seen in the random appearance and disappearance of
PD symptoms, is much less understood but is probably also related to the large fluctuations in
DA release (Hametner et al., 2010).
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Levadopa-induced dyskinesia. Although L-DOPA is the most effective method of
symptom management, as Parkinson’s disease gets worse, efficacy decreases and negative side
effects begin to develop, the most common of which is levodopa-induced dyskinesia (LID)
(Mouradian et al., 1989). Over one third of patients develop dyskinesias within the first five
years of treatment, usually beginning in the limb or side most affected by PD (Calon et al., 2003;
Kobylecki et al., 2010). There are three types of dyskinesias seen most commonly in LID: ON
dyskinesias, biphasic dyskinesias, and OFF period dyskinesias (dystonia; Hametner et al., 2010).
ON dyskinesias are caused by peak levels of L-DOPA and are characterized by chorea (brief
irregular movement) or ballistic movements (Fabbrini, Brotchie, Grandas, Nomoto, & Goetz,
2007). Biphasic dyskinesias occur as L-DOPA concentrations rise and fall past threshold level
and are often comprised of stereotypic, rapid, repeating movements. Dystonia, or sustained
muscle contractions that result in twisting motions or postures, occurs due to subthreshold LDOPA concentrations (Hametner et al., 2010).
The unregulated fluctuations of DA in L-DOPA-treated patients are assumed to produce
dyskinesia, in large part, by overactivation of DA receptors in the striatum, specifically the D1
receptors, which leads, in turn, to an amplification of D1-dependent intracellular signaling
(Darmopil, Martin, De Diego, Ares, & Moratalla, 2009). Indeed, LID is reduced in mice lacking
the D1, but not D2, receptors, suggesting D1 receptors are essential in LID development
(Darmopil et al., 2009). When 6-OHDA lesioned dyskinetic rats were treated with SCH23390, a
specific D1 receptor antagonist, there was a reduction in L-DOPA-induced rotational behavior,
which further suggests LID is mainly due to alterations in D1 receptor function (St. Hilaire,
Landry, Levesque, & Rouillard, 2005). Consistent with this hypothesis, Konradi et al. (2004)
found increased D1 receptor mRNA in dyskinetic 6-OHDA lesioned rats. However, others have
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found no change in mRNA expression, but instead have found increased localization of the D1
receptors at the cell membrane surface thought to be caused by impaired receptor internalization
and trafficking (Aubert et al., 2005; Berthet et al., 2009).
Interestingly, there is also an upregulation of D3 receptor mRNA in the direct pathway,
seen in both dyskinetic 6-OHDA-lesioned rats and MPTP-lesioned nonhuman primates (Bezard
et al., 2003; Van Kampen & Stoessl, 2003). D3 receptors are thought to interact with D1
receptors, increasing sensitization and decreasing receptor internalization (Bezard et al., 2003;
Van Kampen & Stoessl, 2003). Treatment with the D3 receptor antagonist ST 198 decreases LID
expression and normalizes D1 receptor concentration in the plasma membrane (Feyder et al.,
2011).
Closely associated with the sensitization of D1 receptors in the striatum is an increased
coupling of D1 receptors with the Gs/olf protein, leading to an amplification of the downstream
intracellular pathway (Aubert et al., 2005). The overactivation of this G-protein causes increased
activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Darmopil et al., 2009;
Westin, Vercammen, Strome, Konradi, & Cenci, 2007), inactivation of which prevents the
induction of LID (Santini, Valjent, & Fisone, 2007). Additionally, D1 receptor sensitization
causes an increase in DARPP-32 phosphorylation by PKC, resulting in the inhibition of protein
phosphatase-1, which decreases the dephosphorylation of ERK1/2, NMDA receptor subunits,
and AMPA receptor subunits. Increasing evidence suggests that phosphorylation of these
glutamate receptors are an important event in LID development (Cenci, 2010; Santini et al.,
2007), and additional evidence now suggests that dysfunction of DA transmission in the striatum
during PD leads to the increased activity of the glutamate system in the basal ganglia, accounting
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for many of the manifestations of both PD and LID. These data are discussed further in the next
section.
Glutamate
Although the pathology of the motor aspects of Parkinson’s disease and L-DOPAinduced dyskinesia is primarily due to the loss of dopamine in the striatum and attempts to
restore this loss, respectively, it has become increasingly evident that enhanced glutamate
transmission, especially at the NMDA receptor, plays a large role in the development and
expression of both disorders and has therefore been found to be a promising target for the
alleviation of symptoms.
Glutamate and Parkinson’s disease. The depletion of dopaminergic input to the striatum
is thought to cause an increase in corticostriatal glutamatergic transmission onto the indirect
pathway (Gardoni, Ghiglieri, Luca, & Calabresi, 2010). These afferents are regulated by
inhibitory D2 presynaptic dopamine receptors on glutamate terminals (Jonkers, Sarre, Ebinger, &
Michotte, 2002; Rowlands & Roberts, 1980; Yamamoto & Davy, 1992). Without the inhibitory
input of dopamine in Parkinson’s disease there is an increase in activity of these afferents
resulting in the increased release of glutamate (Calabresi, Mercuri, Sancessario, & Bernardi,
1993; Chung et al., 2008; Lievens, Salin, Nieoullon, & Kerkerian-Le Goff, 2001; Nash &
Brotchie, 2002) shown through the increase in glutamate binding to the striatum in patients and
animal models of PD (Nash & Brotchie, 2002; Weihmuller, Ulas, Nguyen, Cotman, & Marshall,
1992). Increased activation of the glutamate receptors of the indirect pathway by excess
extracellular glutamate would cause a downstream disinhibition of the STN, as seen in Figure 1
(Duty, 2010). Overactivation of the STN, as discussed previously, causes a downstream lack of
excitation of the motor cortex, resulting in a loss of movement (Blandini et al., 1996; Duty,
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2010). Additionally, the STN has glutamatergic projections that synapse in the substantia nigra.
In PD when the STN is overactive, excess glutamate is dumped onto the substantia nigra, which
may exacerbate degeneration via excitoxicity (Duty, 2010; Plaitakis & Shashiaran, 2000;
Rodriguez, Herrera, Koistinaho, & Hokfelt, 1999).
Although excess glutamate has been implicated in excitotoxicity, substantial evidence
from animal models indicate that glutamate antagonists, especially at the NMDA receptor, can
reduce the symptoms of PD well after degeneration has occurred. For example, NMDA receptor
antagonists, such as MK-801, CPP, and the NMDA receptor subunit NR2B specific drug Ro 256981, have been found to decrease the motor symptoms of Parkinson’s disease as shown by
improvements in forepaw stepping and increases in contralateral turning in 6-OHDA-lesioned
rats (Kelsey et al., 2004; Loschmann et al., 2004), and by increases in the median mobility scores
in MPTP-lesioned non-human primates (Nash et al., 2000). Additionally, NMDA receptor
antagonists have been shown to potentiate the effects of L-DOPA in non-dyskinetic 6-OHDA
lesioned rats (Kelsey et al., 2004; Klockgether & Turski, 1990; Morelli, Fenu, Pinna, & Chiara,
1992). Antagonism of the metabotropic glutamate receptor mGluR5 with MPEP has also been
shown to potentiate the ameliorative effects of L-DOPA on PD motor symptoms in 6-OHDAlesioned mice (De Leonibus et al., 2009). Direct injections of the NR2B NMDA receptor subunit
antagonist ifenprodil into the striatum (Nash & Brotchie, 2002) and the NMDA receptor
antagonist MK-801 into the STN have also been shown to decrease PD motor deficits in 6OHDA-lesioned rats (Blandini, Greenamyre, Fancellu, & Nappi, 2001). Further indicating that
excess glutamate transmission at NMDA receptors may be causal of PD motor symptoms,
injections of the direct agonist NMDA into the striatum have been shown to induce Parkinsonian
motor deficits in normal rats (Nash & Brotchie, 2002). Treatment of Parkinson’s disease patients
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with NMDA receptor antagonist have had mixed results. A trial of memantine was able to
decrease Parkinsonian symptoms and significantly decrease “off” time, but several subjects
dropped out of the study due to the development of side effects such as abdominal pain,
psychomotor agitation, confusion and dizziness (Rabey, Nissipeanu, & Korczyn, 1992).
Glutamate and LID. Given that PD and LID are assumed to represent opposite effects on
DA transmission, it is surprising to find that glutamate antagonists are successful in reducing
LID as well as the symptoms of PD (Kobylecki et al., 2010; Nash et al., 2000). NMDA
antagonists such as amantadine are highly successful in decreasing motor symptoms of LID in
the MPTP-lesioned nonhuman primate model of PD (Blanchet et al., 1998). Additionally, the
AMPA receptor antagonist IEM 1460 was able to decrease abnormal involuntary movements
(AIMs), a standard measure of LID in animals (Winkler, Kirik, Bjorklund, & Cenci, 2002),
without decreasing the anti-PD effects of L-DOPA in both the 6-OHDA-lesioned rat and the
MPTP-lesioned nonhuman primate (Kobylecki et al., 2010). The combination of a low dose of
the AMPA receptor antagonist GYKI-47261 and the NMDA receptor antagonist MK-801 was
also effective at reducing AIMs in 6-OHDA-lesioned rats (Bibbiani, Oh, Kielaite, Collins, Smith,
& Chase, 2005). The NMDA antagonist amantadine has also been found to reduce the severity of
LID without reducing L-DOPA’s effects on PD in human trials (Snow et al., 2000).
Recently more attention has been paid to metabotropic Group I receptors such as
mGluR5s, antagonism of which decreases the motor dysfunctions and cellular alterations
associated with LID in 6-OHDA-lesioned rats (Mela, Marti, Dekundy, Danysz, Morari, & Cenci,
2007; Rylander et al., 2009) and MPTP-lesioned non-human primates (Johnston, Fox, Mclldowie,
Piggott, & Brotchie, 2010). Similarly, agonists of Group II and III mGlu autoreceptors have been
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shown to be beneficial in the treatment of LID and PD (Cuomo et al., 2009), although not all
studies have found these effects (Murray et al., 2001; Rylander et al,. 2009).
As discussed previously, chronic L-DOPA sensitizes dopamine receptors, especially the
D1 receptors of the direct pathway (Aubert et al., 2005). Activation of the sensitized D1
receptors in the striatum appears to result in increased phosphorylation of NMDA and AMPA
receptors, causing an increase in open-state probability of the ion channels and, thus, increased
transmission (Bagetta, Ghiglieri, Sgobio, Calabresi, & Picconi, 2010; Kobylecki et al., 2010; Oh,
Russell, Vaughan, & Chase, 1998). As described earlier, this increased phosphorylation is
thought to be caused by a D1-dependent increase in cAMP-stimulated protein kinases
(Kobylecki et al., 2010; Oh et al., 1998) and DARPP-32 mediated inhibition of
dephosphorylation (Cenci, 2010; Santini et al., 2007). Indeed, DARPP-32 knock-out mice do not
undergo AMPA receptor phosphorylation and do not develop LID (Santini et al., 2007). This LDOPA-induced sensitization of these glutamate receptors combined with the L-DOPA-induced
increase in glutamate release (Jonkers et al., 2002; Robelet, Melon, Guillet, Salin, & Goff, 2004)
is presumed to result in the increased activity-independent movement seen in LID (Cenci &
Lundblad, 2006).
Limitations of glutamate receptor antagonists. Although glutamate antagonists have been
shown to be effective in ameliorating both PD-like symptoms and LID in animal models of
Parkinson’s disease and in human patients, there are some serious drawbacks that limit their use.
Some NMDA antagonists have worsened LID (Bibbiani et al., 2005) or decreased the antiParkinsonian effects of L-DOPA (Goetz et al., 2007). Additionally, NMDA receptor antagonists
have low therapeutic indexes in humans (Bibbiani et al., 2005; Metman et al., 1998) and often
cause sedation, ataxia, cognitive impairment, and memory loss (Caraci et al., 2012). Because of
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the severity of these side effects, these drugs have generally failed to pass clinical trials (Chu et
al., 2007). Consequently, other means of decreasing excess glutamate transmission are needed.
The next sections focus on the possibility that this may be more safely and efficaciously done by
enhancing the activity of GLT-1, the main glutamate transporter.
GLT-1. Glutamate is not broken down in the synapse but is removed by a member of high
affinity excitatory amino acid transporters (EAATs) (Vemuganti et al., 2001). Within the basal
ganglion the most prevalent transporter is EAAT-2, known as GLT-1 in non-human animals
(Rothstein et al., 1996), which is located primarily on astrocytes (Anderson & Swanson, 2000).
Once inside astrocytes, glutamate is broken down into the less toxic glutamine and transported
back into glutamate neurons (Anderson & Swanson, 2000; Chu et al., 2007). Although there is
variation depending on brain region and presence of other transporters, in most regions,
including the striatum, the majority of synaptic glutamate clearance occurs via GLT-1 (Anderson
& Swanson, 2000; Rothstein et al., 1996).
The ability of GLT-1 to clear glutamate from the synapse is essential for proper neuronal
functioning. Many degenerative diseases, such as amyotrophic lateral sclerosis (ALS),
Alzheimer’s, and Huntington’s disease, are thought to involve a substantial loss of GLT-1 (Beart
& O’Shea, 2007). Without properly functioning GLT-1 there is a massive increase in
extracellular glutamate, as demonstrated through GLT-1 knockout, antisense oligonucleotide,
and pharmacological blockade studies, which causes neuronal death by excitotoxicity (Rothstein
et al., 1996; Selkirk et al., 2005; Vemuganti et al., 2001). Consequently, an increasing number of
researchers have begun to focus on using GLT-1 upregulation to alleviate the symptoms and
degeneration potentially caused by increased glutamate transmission and/or GLT-1
downregulation in several neurodegenerative disorders.
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Ceftriaxone
After an extensive screening of 1040 FDA-approved drugs, Rothstein et al. (2005)
discovered that β-lactam antibiotics cause a massive upregulation of GLT-1 expression, and the
most clinically useful and effective β-lactam antibiotic was ceftriaxone. Although other β-lactam
antibiotics such as penicillin caused a greater increase in GLT-1, ceftriaxone more easily crosses
the blood brain barrier and has minimal side effects (Nau et al., 1993). Conveniently, the
concentration of ceftriaxone in the cerebrospinal fluid required to upregulate GLT-1 falls within
the range approved by the FDA for treatment of meningitis, making it a very promising
candidate for passing clinical trials (Rothstein et al., 2005). In fact, ceftriaxone has recently
begun stage III clinical trials for the treatment of ALS (Traynor et al., 2006).
Behavioral effects. Ceftriaxone has been used successfully in a number of studies on
animal models to decrease extracellular glutamate and act as a neuroprotective agent. In their
original study, Rothstein et al. (2005) found that daily injections of 200 mg/kg ceftriaxone
beginning at the time of symptom onset in a mouse model of ALS were able to delay loss of
strength and body weight in addition to significantly increasing survival by 10 days. Additionally,
5 days of pretreatment with either 100 or 200 mg/kg ceftriaxone has been found to be
neuroprotective in the transient focal cerebral ischemia model of stroke, significantly decreasing
cell death (Chu et al., 2007). This effect was blocked by an injection of 10 mg/kg dihydrokainate
(DHK), a specific GLT-1 blocker, indicating that the neuroprotective effects of ceftriaxone were
indeed due to increased glutamate uptake by GLT-1 (Chu et al., 2007). Further indicating that
ceftriaxone is effective because it enhances GLT-1 expression and/or activity, antibiotics that do
not have these effects on GLT-1 are not neuroprotective in animal models in which ceftriaxone is
neuroprotective (Rothstein et al., 2005). When tested in the R6/2 mouse model of Huntington’s
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disease, 5 days of 200 mg/kg ceftriaxone was able to decrease early stage Huntington’s
associated motor dysfunctions, such as paw clasping, twitching, and motor inflexibility for the
duration of treatment (Miller et al., 2008). Moreover, some effects on motor symptoms lasted for
at least a week following ceftriaxone cessation. Because the motor symptoms of Huntington’s
disease in this model develop before there is significant cell death in the striatum (Miller et al.,
2008), it is possible that ceftriaxone decreases these symptoms not just by decreasing
excitotoxicity, but also by normalizing the effects on neural transmission produced by excess
glutamate.
Further indicating that ceftriaxone can be effective in normalizing some behaviors in the
absence of excitotoxicity, daily injections of 50, 100, and 200 mg/kg ceftriaxone were able to
dose-dependently decrease morphine analgesic tolerance in rats. These effects were blocked by
an injection of 10 mg/kg DHK, showing this effect was due to an increase in glutamate uptake by
GLT-1 (Rawls, Zielinski, Patel, Sacavage, Baron, & Patel, 2010). Similarly, 100 and 200 mg/kg
ceftriaxone given daily over 5 days of extinction training following cocaine self-administration
were able to decrease subsequent cocaine-induced relapse in rats (Sari, Smith, Ali, & Rebec,
2009). Thus, it is quite clear that ceftriaxone, by enhancing GLT-1 function, can normalize
behaviors caused by excess glutamate transmission as wall as reduce glutamate-induced
excitotoxicity. As a consequence, ceftriaxone should be helpful in reducing some of the motor
disturbances associated with Parkinson’s disease. Interestingly, there was no change in behavior
in any of the control animals given ceftriaxone compared to those given saline (Miller et al.,
2008; Sondheimer & Knackstedt, 2011), suggesting that it may not produce many side effects.
Mechanisms. Several studies have shown that ceftriaxone dose-dependently increases
GLT-1 expression (Rothstein et al., 2005) and that its actions are specific to GLT-1, as the levels
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of the other common glutamate transporters, GLAST and EAAC1, are unchanged by ceftriaxone
treatment (Lee et al., 2008; Lievens et al., 2001; Rothstein et al., 2005). GLT-1 upregulation has
been shown by the upregulation of GLT-1 mRNA (Lee et al., 2008; Rothstein et al., 2005), total
GLT-1 protein (Miller et al., 2008; Sari, Prieto, Barton, Miller, & Rebec, 2010; Sondheimer &
Knackstedt, 2011), and GLT-1 expression on the cell surface, with the maximum GLT-1
expression occurring following injections of 200 mg/kg (Rothstein et al., 2005). GLT-1 mRNA
upregulation typically reaches a maximum after 3 days of ceftriaxone injections while protein
expression is typically maximized after 5 days of injections (Chu et al., 2007). These increases in
GLT-1 have been seen to last from 20 days to 3 months after the last injection of ceftriaxone
(Rasmussen et al., 2011; Rothstein et al., 2005). More critically, these increases in GLT-1
expression have been associated with long lasting decreases in extracellular glutamate
(Rasmussen et al., 2011). In fact, evidence indicates that ceftriaxone can increase glutamate
uptake in the absence of increased GLT-1 expression, presumably reflecting an increase in GLT1 activity. For example, Thone-Reinke et al. (2008) found that a single acute injection of 200
mg/kg ceftriaxone 90 min after transitive focal ischemia was neuroprotective without increasing
GLT-1 mRNA or protein expression. However, the acute injection did increase glutamate
clearance. Although Lipski et al. (2007) found no increase in GLT-1 after five injections of 200
mg/kg ceftriaxone, they did find evidence for increased GLT-1 function.
Increased GLT-1 expression may be due to an increase in the activation of the GLT-1
promoter fragment (Rothstein et al., 2005). Subsequent research by Lee et al. (2008) showed
ceftriaxone increased binding of nuclear factor-κB to the GLT-1 promotor at position -272.
Ceftriaxone does this by causing the degradation of the NF-κB inhibitor protein IκBα. Once NF-
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κB is disinhibited it can then be translocated into the nucleus. Inhibition of NF-κB with
Ad.IκBα-mt32 blocks the effects of ceftriaxone (Lee et al., 2008).
However, these effects do not explain the action of ceftriaxone when there is no increase
in GLT-1 protein. Recently it has been suggested that a palmitic acid molecule must be attached
to GLT-1 through the process of palmitoylation in order to function correctly. Palmitoylation is
thought to cause the increased tethering of GLT-1 to the membrane through the attachment of a
palmitic acid molecule to a cysteine residue on the protein (Huang et al., 2010). It is thus
possible that ceftriaxone may increase GLT-1 activity (with or without increased expression) by
directly increasing palmitoylation, which, for example, is disrupted in some Huntington’s disease
models (Huang et al., 2010). Additionally, ceftriaxone may increase GLT-1 activity through its
ability to chelate metals, which would reduce the toxic effect of some metal ions and the
associated oxidative stress that would normally decrease GLT-1 activity and expression (Ji, Shen,
& Zhang, 2005; Lipski et al., 2007).
Rationale for Experiments
These studies effectively indicate that ceftriaxone can reduce glutamate-induced
excitotoxicity and other behavioral effects of excess glutamate transmission in a variety of
animal models by increasing glutamate clearance from the synapse through upregulation of the
expression and/or activity of GLT-1. Thus, in so far as some of the behavioral effects of PD and
LID are due to excess glutamate transmission (Jonkers et al., 2002; Robelet et al., 2004), it seems
reasonable to suggest that ceftriaxone would be effective in reducing both of these motor effects,
perhaps without the side effects of glutamate receptor antagonists. Thus the intent of my study is
to determine if injections of ceftriaxone will ameliorate the contralateral forepaw stepping
deficits produced by unilateral medial forebrain injections of 6-OHDA in rats and the subsequent
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increase in LID produced by repeated injections of 10 mg/kg L-DOPA. Because the degeneration
produced by 6-OHDA occurs quickly, it is likely that any effects of ceftriaxone in this model
will be on symptom expression rather than on ongoing excitotoxic degeneration.
In Experiment 1, I examined the effects and timecourse of daily injections of 100 mg/kg
ceftriaxone on stepping with the impaired contralateral forelimb, which is a measure of
bradykinesia (Olsson, Nikkah, Bentlage, & Bjorklund, 1995). A dose of 100 mg/kg ceftriaxone
was chosen because prior studies have indicated that its effects on glutamate transport
(Rasmussen et al., 2011) and behavior are similar to those of the more commonly used 200
mg/kg (Chu et al., 2007; Rawls et al., 2010b; Sari et al., 2009). Given the success of 100 mg/kg
ceftriaxone in Experiment 1, in Experiment 2 I examined the effectiveness of acute and subchronic injections of 50 mg/kg ceftriaxone in the treatment of PD in half the animals, as in
Experiment 1. I then induced LID in these animals with daily injections of 10 mg/kg L-DOPA to
determine if concurrent ceftriaxone could slow the development of LID without decreasing the
effects of L-DOPA on forepaw stepping. The severity of LID was measured using the Abnormal
Involuntary Movement (AIM) Scale which evaluates four AIM subtypes: contralateral turning,
axial dystonia, forelimb dyskinesia, and orolingual dyskinesia (Lee et al., 2000; Lundblad,
Andersson, Winkler, Kirik, Wierup, & Cenci, 2002; Winkler et al. 2002). In the other half of the
animals, LID was induced before ceftriaxone treatment began to determine if ceftriaxone could
reduce the expression of established LID. I then determined if the GLT-1 antagonist DHK could
block the effect of ceftriaxone on forepaw stepping.
Experiment 1: Effect of 100 mg/kg Ceftriaxone on Forepaw Stepping.
Method
Subjects
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Eleven Long Evans rats from Charles River Laboratory (Wilmington, MA) were
individually housed in plastic cages (45 x 25 x 20 cm) with corncob bedding in a room with a
12-hour light cycle. Rats had unlimited access to food and water except 24 hr before surgery and
during behavioral testing. All procedures were approved by Bates College Institutional Animal
Care and Use Committee.
Surgery
Rats were anesthetized with an intraperitoneal (i.p.) injection of a 1 ml/kg combination of
ketamine (100 mg/ml; Sigma Chemicals, St. Louis, MO) and xylazine (10 mg/ml; Astra
Pharmaceutical Products, Westborough, MA) in water. They were then placed in a stereotax
(Kopf Instruments, Tujunga, CA) with the incisor bar 3.3 mm below interaural line.
Noradrenergic neurons were protected from 6-OHDA by an i.p. injection of desipramine (1
ml/kg of 25 mg/kg in 0.9% saline; Sigma Chemicals, St. Louis, MO) given shortly after
placement of the rat in the stereotax. A flat-tipped 5-µl Hamilton syringe was used to inject 2 µl
of 6-OHDA (6 µg/µl dissolved in a 0.9% saline solution) at a rate of 0.25 µl/min. 6-OHDA
(Sigma Chemicals, St. Louis, MO) was thawed from frozen aliquots immediately before
injection into the left medial forebrain bundle 4.7 mm posterior to bregma, 7.8 mm ventral to
skull surface, and 1.4 mm left of midline. The syringe was left in place for 5 min post injection.
Following surgery, rats were injected subcutaneously (s.c.) with 5 mg/kg Rimadyl (1 ml/kg;
Hospira, Lake Forest, IL) and 5 ml Lactate Ringers Solution (Bimeda-MTC Animal Health,
Ontario Canada).
Measurement of Forepaw Stepping
Motor impairment was measured by counting medial and backward steps taken with each
forepaw over 1 m on a canvas belt treadmill moving at a speed of 0.1 m/s. One forepaw was
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restrained while the rat was held at an angle so that its hind legs were approximately 5 cm above
the treadmill surface such that the forepaw was placed on the moving belt. Backward stepping
was measured by holding the rat’s long axis parallel to the treadmill, whereas medial stepping
was measured while holding the rat perpendicular to the treadmill, with the belt moving away
from the rat in both cases. Testing consisted of three trials for both forepaws in both directions.
The starting position was rotated after each trial, with trial one starting with ipsilateral (left)
backward, contralateral (right) backward, ipsilateral medial, contralateral medial. Trial two
began with contralateral backward, ended with ipsilateral backward, and so forth.

Procedure
Table 1. Timeline of Experiment 1. The abbreviations at the bottom refer to the corresponding days in Figure 2: B =
baseline, 6 LD = 6 mg/kg L-DOPA, C = 100 mg/kg ceftriaxone, and P = post-. The trailing numbers refer to the
day(s) in that condition during which testing occurred.

1-4
Baseline

5
6 mg/kg LDOPA

7-13
Ceft

B4

6 LD

C1-C7

Day
14
6 mg/kg LDOPA &
Ceft
6 LDC8

15
Ceft

16-45
Post Ceft

46
Acute
Ceft

47
Post
Ceft

C9

PC1-PC30

Acute C

C

See Table 1 for timeline of Experiment 1. Forepaw stepping was initially measured for 4
days beginning around 1 week post-surgery to determine baseline impairment caused by the
lesion. Two rats were excluded from further testing due to a lack of impairment in stepping; their
impairment in right forepaw stepping compared to left forepaw stepping was less than 15%. The
acute effect of an i.p. 1 mg/kg injection of 6 mg/kg L-DOPA (dissolved in 0.1% sodium
metabisulfite in water with 6.25 mg/ml benserazide; all drugs were from Sigma Chemicals, St.
Louis, MO) on forepaw stepping was then measured in the nine impaired rats 30 min after the
injection. Two of these rats were also tested 24 hr post-L-DOPA, prior to the injection of
ceftriaxone (see below), to determine the duration of L-DOPA’s effects.
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Ceftriaxone (100 mg/kg in 0.9% saline; Sigma Chemicals, St. Louis, MO) was then
administered i.p. at 1 ml/kg daily for 9 days to all rats to determine the effect of subchronic
administration of ceftriaxone on forepaw stepping. Animals were tested 24 hr after each injection
and were given subsequent injections immediately after testing.
On the eighth day of ceftriaxone testing (day 14), animals were also injected with 6
mg/kg L-DOPA (1 ml/kg) 30 min before testing to determine if a moderate dose of L-DOPA has
an additive effect with ceftriaxone on forepaw stepping. On the ninth day, the rats then received
their last dose of ceftriaxone.
Forepaw stepping after cessation of ceftriaxone was measured periodically over 30 days
to observe the time course of the decrease in ceftriaxone’s effects. On post-ceftriaxone day 31
(day 46), 100 mg/kg ceftriaxone was given acutely 45 min before forepaw step testing, and
stepping was also measured 24 hr later with no additional injections.
Results
Stepping
Figure 2 shows the changes in mean (± SEM) steps with both forepaws throughout the 47
days of Experiment 1.
6 mg/kg L-DOPA. On the day following the 4th baseline day, the rats were tested after an
acute injection of 6 mg/kg L-DOPA. The Forepaw (right, left) × Condition (fourth day of
baseline [B4], L-DOPA [6 LD]; see Figure 2) repeated measures analysis of variance (ANOVA)
showed a main effect of forepaw, F(1, 8) = 281.63, p < .001, indicating that the rats stepped less
with their right forepaw than their left forepaw. There was also a main effect of condition, F(1, 8)
= 23.75, p < .005, indicating that 6 mg/kg L-DOPA improved stepping. Finally, there was also a
Forepaw × Condition interaction F(1, 8) = 57.79, p < .001, and subsequent simple effects tests
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showed the animals stepped less with the right forepaw irrespective of condition, Fs(1, 16) >
161.95, ps < .001, and that 6 mg/kg L-DOPA increased stepping with the impaired right forepaw,
F(1, 16) = 74.32, p < .001, but not the left forepaw.
30
Right Forepaw
Left Forepaw

Mean Steps (+ SEM)

25

20

15

10

5

0

Drug Conditions

Figure 2. The change in mean steps (± SEM) taken with both left and right forepaws throughout
the course of Experiment 1. The letters refer to the drug condition (B = baseline; 6 LD = 6 mg/kg
L-DOPA; C = 100 mg/kg ceftriaxone; P = post-), and the trailing numbers refer to the day in that
condition.
100 mg/kg ceftriaxone. The rats were then injected with 100 mg/kg ceftriaxone for 7 days,
and stepping was compared to baseline. The Forepaw (2) × Day (baseline [B4] and 7 days of
ceftriaxone [C1 – C7]; see Figure 2) repeated measures ANOVA showed main effects of
forepaw, F(1, 8) = 166.75, p < .001, and day, F(7, 56) = 35.46, p < .001, and a Forepaw × Day
interaction, F(7, 56) = 24.99, p < .001. Simple effects tests showed the animals stepped less with
their right forepaw than with their left forepaw across all days, Fs(1, 64) > 49.96, p < .001. More
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critically, simple effects tests indicated that, compared to baseline, repeated injections of 100
mg/kg ceftriaxone progressively increased right forepaw stepping, F(7, 112) = 59.84, p < .001,
which seemingly reached asymptote after five injections, as pairwise comparisons indicated that
stepping on the last 3 days (C5 - C7) did not differ. There was no effect of ceftriaxone on left
forepaw stepping.
6 mg/kg L-DOPA combined with 100 mg/kg ceftriaxone. The rats were then given an
acute injection of 6 mg/kg L-DOPA combined with ceftriaxone, and the data were compared to
the prior and succeeding days of ceftriaxone alone. The Forepaw (2) × Condition (seventh
injection of ceftriaxone [C7], 6 mg/kg L-DOPA [6 LDC8], post-L-DOPA [PLDC9]; see Figure 2)
repeated measures ANOVA showed only a main effect of forepaw, F(1, 8) = 95.20, p < .001.
Although 6 mg/kg L-DOPA tended to improve right forepaw stepping even further, this additive
effect was not significant.
Ceftriaxone abstinence. The ceftriaxone injections were then stopped for 30 days to
determine the duration of its effects, and the rats were tested periodically. The Forepaw (2) ×
Day (baseline [B4] and 11 post-ceftriaxone tests [PC1 – PC30]; see Figure 2) repeated measures
ANOVA showed main effects of forepaw, F(1, 5) = 187.00, p < .001, and day, F(11, 55) = 48.77,
p < .001, and a Forepaw × Day interaction, F(11, 55) = 27.90, p < .001. Subsequent simple
effects tests showed that the animals stepped less with their right than left forepaw on all days,
Fs(1, 60) > 53.89, ps < .001, and that right forepaw stepping decreased across days, F(11, 110) =
74.71, p < .001, while left forepaw stepping slightly increased, F(11, 110) = 2.28, p < .02 . As
can be seen in Figure 2, pairwise comparisons indicated that the effects of ceftriaxone did not
begin to decrease until the 16th day of abstinence, F(1, 110) = 4.57, p < .05. Although stepping
decreased progressively thereafter, it had still not returned to baseline by the 30th day of

29
abstinence, F(1, 110) = 37.83, p < .001. Left forepaw stepping was greater than baseline through
the 19th day of abstinence, Fs(1, 110) > 4.96, ps < .05, and no significant changes occurred
during the course of abstinence.
500

Mean Body Weight (gm)
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Figure 3. The change in mean body weight (± SEM) in gm over the course of the experiment. As
in Figure 2, the letters on the x-axis refer to the drug condition (B = baseline; 6 LD = 6 mg/kg LDOPA; C = 100 mg/kg ceftriaxone; P = post-), and the trailing numbers refer to the day in that
condition.
Acute 100 mg/kg ceftriaxone. The animals were then re-tested 45 min following an acute
injection of ceftriaxone, and the data were compared to the preceding and succeeding days
without ceftriaxone. The Forepaw (2) × Condition (post-ceftriaxone day 30 [PC30], acute
ceftriaxone [Acute C], 24 hr post-ceftriaxone [PC]; see Figure 2) repeated measures ANOVA
showed main effects of forepaw, F(1, 5) = 1268.79, p < .001, and condition, F(2, 10) = 26.18, p
< .001, and Forepaw × Condition interaction, F(2, 10) = 47.60, p < .001. Simple effects tests
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showed the animals stepped less with their right forepaw on all days, Fs(1, 15) > 417.77, ps
< .001, and that ceftriaxone increased right forepaw stepping, F(2, 20) = 63.82, p < .001, without
affecting left forepaw stepping. Pairwise comparison showed the acute dose of ceftriaxone
increased right forepaw stepping compared to post-ceftriaxone day 30, F(1, 20) = 55.19, p < .001,
and that this effect was even larger 24 hr later, F(1, 20) = 13.37, p < .005.
Weight. A one-way repeated measures ANOVA on the weights from the last day of
baseline through the end of the experiment for the six animals for whom all weights were
available revealed a main effect, F(25, 125) = 30.15, p < .001 (see Figure 3). Subsequent
pairwise comparisons indicated that weights did not change from baseline until the 13th day of
abstinence from ceftriaxone, F(1, 125) = 36.70, p < .001, suggesting that ceftriaxone suppressed
weight gain.
Discussion
Unilateral 6-OHDA lesions
Lesions to the left medial forebrain bundle (MFB) caused an 81% decrease in forepaw
stepping in the impaired right forepaw, contralateral to the lesion, compared to the unimpaired
ipsilateral left forepaw during baseline testing. This level of impairment is consistent with
previous data from our lab showing the same lesion causes a 68-87% decrease in forepaw
stepping (Kelsey et al., 2004). This degree of impairment is usually found in MFB lesions that
produce greater than 80% depletion of dorsal striatal DA (Chang, Wachtel, Young, & Kang,
1999), although it has been found to occur with less DA depletion (Kelsey et al., 2004).
Although a neurochemical assessment of lesion damage has not been performed yet, it is likely
that these lesions have produced an average of 80% decrease in dorsal striatal DA and its
metabolites compared to the unlesioned side.
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6 mg/kg L-DOPA
The acute injection of 6 mg/kg L-DOPA caused a 23% increase in right forepaw stepping
compared to baseline, without affecting left forepaw stepping. Percent improvement was
computed as the percentage of steps taken with the right forepaw compared to those taken with
the left forepaw when injected with L-DOPA minus the same percentage on the preceding
baseline day. This finding is also consistent with previous findings that this and similar doses of
L-DOPA improved, but did not normalize, forepaw stepping (Chang et al., 1999; Kelsey et al.,
2004). Although the data are not shown, right forepaw stepping had returned to baseline in the
two animals tested on the day following this L-DOPA injection, also consistent with prior
findings from our lab (Kelsey et al., 2004; Kelsey, Langelier, Oriel, & Reedy, 2009).
100 mg/kg ceftriaxone
One day after the first injection of 100 mg/kg ceftriaxone, right forepaw stepping had
significantly increased by 18% compared to baseline. Right forepaw stepping progressively
improved with subsequent injections, reaching an apparent maximum improvement of 44% after
five injections, although still not normalizing stepping. Furthermore, this improved stepping was
not further enhanced by an injection of 6 mg/kg L-DOPA, consistent with data indicating that
there appears to be a ceiling above which impaired forepaw stepping cannot be further improved
(Kelsey et al., 2004; Kelsey et al., 2009).
Moreover, in contrast to the therapeutic effects of L-DOPA, which disappear within 24 hr,
the therapeutic effects of ceftriaxone are long lasting. After ceftriaxone treatment ceased, the
ameliorative effects of ceftriaxone on right forepaw stepping continued until at least 16 days
after the last injection. At this point stepping began to progressively decrease, although stepping
still had not returned to baseline after 30 days of abstinence. Finally, although stepping had not
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yet returned to baseline, right forepaw stepping still improved by 18% 45 min after an acute
injection of ceftriaxone and by an additional 6% the following day. Although Miller et al. (2008)
found that the behavioral effects of ceftriaxone decreased to the level of saline animals within 7
days of the last injection of ceftriaxone in an animal model of Huntington’s, the progressive
degeneration that occurs in the HD model may limit the ability of ceftriaxone to maintain its
effectiveness.
In summary, acute injections of 100 mg/kg ceftriaxone increased right forepaw stepping
in this model as effectively as 6 mg/kg L-DOPA, and daily injections further increased right
forepaw stepping without affecting left forepaw stepping. Moreover, this impressive therapeutic
effect did not decline until 16 days of ceftriaxone abstinence and was still apparent after 30 days
of abstinence. The rapid onset of these therapeutic effects in the absence of apparent side effects
and the long duration of these effects suggest that ceftriaxone may be a superior treatment to the
short lasting effect of L-DOPA and other approved therapies.
Although similar doses of ceftriaxone have been found to be effective in reducing
symptoms in models of other degenerative disease such as ALS and Huntington’s disease (Miller
et al., 2008; Rothstein et al., 2005), this appears to be the first study to examine its effects on an
animal model of PD. Moreover, in contrast to those studies, the improvement in PD-like
symptoms that I observed is not likely to be due to a decrease in ongoing neurodegeneration as
ceftriaxone was not administered until 14 days after the 6-OHDA injection, well after
degeneration occurred. Rather, these data suggest an effect on symptom expression.
Because there is no significant upregulation of GLT-1 protein until 2 days after the first
injection (Chu et al., 2011; Rothstein et al., 2004), it can be hypothesized that the effect of
ceftriaxone on forepaw stepping seen after the acute and first couple of injections is most likely
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not due to GLT-1 upregulation, and is probably due to an increase in GLT-1 activity (Lipski et
al., 2007; Thone-Reineke et al., 2008). However, the subsequent increase in stepping with a
maximum effect after five injections corresponds to the finding that GLT-1 protein expression
reaches a maximum at that time (Chu et al., 2007). Similarly, the findings that GLT-1
upregulation lasts for 3 months following the final injections (Rothstein et al., 2005) and that
extracellular glutamate was decreased for at least 20 days (Rasmussen et al., 2011) are consistent
with my finding that stepping was still elevated 30 days after ceftriaxone removal. Thus, I
propose that it is most likely that ceftriaxone’s ability to decrease motor impairment in 6-OHDAlesioned rats is due to its ability to decrease extracellular glutamate (Rasmussen, et al., 2011),
consistent with the finding that blocking glutamate transmission with NMDA and AMPA
receptor antagonists is ameliorative in animal models of PD and human PD patients (Kelsey et
al., 2004; Loschmann et al., 2004; Nash et al., 2000).
Body Weight
It would appear as though chronic injections of 100 mg/kg ceftriaxone suppressed weight
gain until 2 weeks after treatment had ceased. As far as I can tell, this effect has not been noted
consistently in humans, although it is listed as a rare side effect.
Experiment 2: Effect of 50 mg/kg Ceftriaxone on Forepaw Stepping and L-DOPA-Induced
Dyskinesia.
Experiment 2 was designed to clarify and extend the findings of Experiment 1. Although
50 mg/kg ceftriaxone has failed to show behavioral or GLT-1 effects in other studies (Rawls et
al., 2010), given the substantial effects of 100 mg/kg ceftriaxone in Experiment 1, I chose to
examine the effects of 50 mg/kg ceftriaxone in this experiment. Additionally, I wanted to
determine if an acute effect of ceftriaxone could be demonstrated more cleanly. I also chose to
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use a second group that initially received saline in order to demonstrate that the ability of
ceftriaxone to improve stepping was not merely an effect of practice. Both groups were
subsequently repeatedly injected with 10 mg/kg L-DOPA to induce LID, which enabled me to
determine if ceftriaxone could reduce both the development and expression of LID. Most
importantly I wanted to determine if the effects of ceftriaxone were due to an increase in GLT-1
function by seeing if selectively blocking GLT-1 with dihydrokainate (DHK) would decrease the
therapeutic effects of ceftriaxone on stepping.
Method
Subjects
Seventeen rats were purchased from Charles River were used and housed as in
Experiment 1. All procedures were approved by the Bates College Institutional Animal Care and
Use Committee.
Surgery
Surgery was conducted as in Experiment 1.
Drugs
All drugs were obtained and prepared as in Experiment 1 unless otherwise noted.
Behavioral Measures
Stepping. Stepping was measured as in Experiment 1.
Abnormal involuntary movements (AIMs) rating. Each rat was observed individually for
levodopa-induced dyskinesia (LID) in a clear plastic cage (45 x 25 x 20 cm) with corncob
bedding 30 and 60 min after the injection of L-DOPA. LID was quantified using the rat AIMs
rating scale (Winkler, Kirik, Bjorklund, & Cenci, 2002). Four different subtypes of rat AIMs
were measured for severity: limb dyskinesia, axial dystonia, orolingual dyskinesia, and
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contralateral rotation (see Table 2 for details and scoring). In addition, the amplitude of forelimb
and axial AIMs were also measured (see Table 2 for scoring). The scales for the two tests were
added, and the maximum attainable score each day was 48.
Table 2. Rating scale for abnormal involuntary movements (AIMs) in the rat.
AIMs subtypes criteria
Limb
Repetative, rhythmic jerky movements or dystonic posturing of the forelimb on
the side contralateral to the dopamine-denervated striatum, opening/closing of
digits and promation/supination of the wrist.
Axial
Lateral deviation or torsion of the head, neck, trunk towards the side contralateral
to the dopamine-denervated striatum.
Orolingual
Repetitive chewing movements of the jaw, tongue protrusion, facial grimacing,
biting (either injurious or noninjurious) of the fur and skin on the forelimb
contralateral to the lesion.
Contralateral Circular locomotion contralateral to the dopamine-denervated striatum in which
Rotation
all four paws contacted the floor during turning.
Severity Scale
0
Absent
1
Occasional- present less than 50% of observation time
2
Frequent- present more than 50% of observation time
3
Continuous but interrupted by strong sensory stimuli (ie., loud tap on cage)
4
Continuous, can not be interrupted by strong sensory stimuli
(Adapted from Winkler et al., 2002)
Amplitude Scale
Axial
Angle is estimated with respect to the deviation from (or torsion around) the
AIMs
longitudinal axis of the body
0
Absent
1
Consistent lateral deviation of head and neck at ~30 degree angle
2
Lateral deviation of head and neck to an angle between 30 and 60 degrees
3
Lateral deviation and/or torsion of head, neck and upper trunk to an angle between
60 and 90 degrees
4
Torsion of head, neck and trunk at > 90 degree angle, causing the rat to lose balance
Forlimb
AIMs
0
1
2
3
4

Absent
Tiny oscillatory movements of the paw and distal forelimb around a fixed point
Movements of low amplitude but causing visible contraction of the shoulder muscles
Translocation of the whole limb with visible contraction of shoulder muscles
Vigorous limb and shoulder movements of maximal amplitude, may have a ballistic
character
(Adapted from Winkler et al., 2002)
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Procedure
Table 3. Timeline of Experiment 2. The abbreviations at the bottom of each row refer to the corresponding days in
Figures 2 and 3: B = baseline, S = saline, C = 50 mg/kg ceftriaxone, LD = 6 and 10 mg/kg L-DOPA, and DHK = 10
mg/kg DHK. The trailing numbers refer to the day(s) in that condition during which testing occurred.

Group
Saline

1-4
Baseline

7-16
Saline

S1

S2-S10

Baseline

Acute
Ceft

Ceft

6 mg/kg
L-DOPA
& Ceft

B4

Acute
C

C2-C10

6 LD1C12

B4
Ceftriaxone

Day
18
19-30
6 mg/kg
10 mg/kg
L-DOPA
L-DOPA
& Saline
& Saline
LD4S156 LD1S12 LD10S21

5
Saline

10 mg/kg
L-DOPA
& Ceft
LD4C15LD10C21

31-37
L-DOPA &
Ceft

38-39
Ceft

40
Ceft &
DHK

41
None

LD12C1LD16C5

C7

C9DH
K

C10

L-DOPA &
Ceft

L-DOPA
& Ceft

LD12C23LD16C27

LD18C29

See Table 3 for a timeline of Experiment 2. As in Experiment 1, baseline forepaw
stepping was measured in 17 rats for 4 days, beginning approximately 1 week after surgery. One
rat was excluded due to insufficient impairment. The rats were then divided into two equally
impaired groups: a ceftriaxone group and a saline group. In eight of the rats, the acute effect of
50 mg/kg ceftriaxone (1 ml/kg i.p. in 0.9% saline; Sigma Chemicals, St. Louis, MO) on forepaw
stepping was measured 45 min after injection, whereas eight others were tested after an injection
of 0.9% saline. On the following day, the rats began receiving daily injections of either 50 mg/kg
ceftriaxone or 0.9% saline for 10 additional days, at which point an asymptote appeared to be
reached in the ceftriaxone animals. In order to accommodate all 16 animals, forepaw stepping
was measured every other day, for a total of 6 out of 11 days. As in Experiment 1, on test days,
the rats received their saline or ceftriaxone injections immediately following testing.
The acute effect of 6 mg/kg L-DOPA was measured on forepaw stepping and AIMs in all
rats on day 18, as in Experiment 1. The following day all rats began receiving daily 1 ml/kg i.p.
injections of 10 mg/kg L-DOPA (dissolved in 0.1% sodium metabisulfite in water with 6.25
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mg/ml benserazide; Sigma Chemicals, St. Louis, MO) along with injections of saline or
ceftriaxone for 12 days in order to induce LID. Testing now occurred every third day for a total
of four tests. On testing days, AIMs were measured 30 and 60 min after the L-DOPA injection,
and forepaw stepping was measured between the two AIMs tests. On test days, saline or
ceftriaxone injections were given immediately after the second AIMs test.
AIMs in the saline group appeared to reach asymptote after 13 days (4 tests) of L-DOPA
treatment, at which point 50 mg/kg ceftriaxone was given daily for 7 days, instead of 0.9% saline,
to determine if ceftriaxone could decrease the expression of pre-established LID. Testing
continued as before except that it occurred 45 minutes after the first ceftriaxone injection and
every other day after that for a total of three tests. Beginning on the day following the last test
(LD16C5), injections of L-DOPA were discontinued, but daily ceftriaxone injections continued,
and the rats were retested 24 hr after L-DOPA removal (C7). The original ceftriaxone group
continued to receive daily L-DOPA and ceftriaxone injections through day 38 at which point
they were not tested further.
After a third day without L-DOPA (day 40), the original saline-injected rats were given
an acute injection of 10 mg/kg the GLT-1 antagonist dihydrokainic acid (DHK; 1 ml/kg i.p. in
0.1 M phosphate buffered saline; Tocris, Minneapolis, MN) 45 min before forepaw stepping to
see if selective blockade of GLT-1 would reverse the anti-Parkinsonian effects of ceftriaxone.
Immediately following this test, these rats received their last injection of ceftriaxone, and the rats
were tested for forepaw stepping on the following day and then periodically thereafter to
determine the duration of ceftriaxone’s effects.
Results
Stepping
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Figure 4. The change in mean steps (± SEM) taken with both left and right forepaws throughout
the course of Experiment 2. The letters refer to the drug condition (B = baseline; C = 50 mg/kg
ceftriaxone; LD = 6 and 10 mg/kg L-DOPA; DHK = 10 mg/kg DHK), and the trailing numbers refer
to the day in that condition during which testing occurred. The symbols to the left of the
backslash refer to the original saline-injected group, and the numbers to the right refer to the
original ceftriaxone-injected group.
50 mg/kg ceftriaxone. Following the last baseline test (B4), the eight saline-injected rats
received daily injections of saline during the first 10 days of this experiment (S1 – S10) while the
ceftriaxone-injected rats received daily injections of 50 mg/kg ceftriaxone (acute C1– C10).
Testing occurred every other day. The Forepaw (2) × Day (fourth day of baseline and 6 tests
during the saline or ceftriaxone injections [B4 – S10/C10]) x Group (saline, ceftriaxone)
ANOVA with repeated measures on forepaw and day showed a main effects of forepaw, F(1, 14)
= 2384.94, p < .001, day, F(6, 84) = 37.14, p < .001, and group, F(1, 14) = 82.95, p < .001 (see
Figure 4). All of the two-way interactions were significant, as was the triple interaction, F(6, 84)
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= 22.96, p < .001. Subsequent simple, simple effects tests indicated that both groups of rats
stepped less with their right forepaw than with their left on all days, Fs(1, 98) > 207.14, ps
< .001, and that 50 mg/kg ceftriaxone increased stepping with both forepaws, Fs(6, 168) > 4.04,
ps < .001, while saline injections had no effect on either forepaw. Subsequent pairwise
comparisons indicated that acute ceftriaxone increased right forepaw stepping above baseline,
F(1, 168) = 81.07, p < .001, and that right forepaw stepping progressively increased until
reaching asymptote after the sixth injection. As a consequence, the ceftriaxone-injected rats were
already stepping more with their right forepaw than the saline-injected rats by the first acute
injection of ceftriaxone, Fs(1, 196) > 42.28, ps < .001. Left forepaw stepping gradually increased
across days in the ceftriaxone-treated rats such that they were stepping more with their left
forepaw on the 10th day of treatment than they were on baseline through the fourth injection of
ceftriaxone, Fs(1, 168) > 6.74, ps < .02. There were no differences between the saline- and
ceftriaxone-treated rats on left forepaw stepping.
L-DOPA. The daily saline or ceftriaxone injections were continued, but all rats were also
injected with 6 mg/kg L-DOPA once and then 10 mg/kg L-DOPA daily for 10 days and were
tested every third day. The Forepaw (2) × Day (saline/ceftriaxone day 10 [S10/C10] through four
L-DOPA tests [6 LD1S12/6 LD1C12 - LD10S21/LD10C21]) × Group (L-DOPA combined with
saline or ceftriaxone) ANOVA with repeated measures on forepaw and day showed a main effect
of forepaw, F(1, 14) = 165.14, p < .001, day, F(4, 56) =4.39, p < .005, and group, F(1, 14) =
7.16, p < .02 (see Figure 4). All two–way interactions with day were significant as was the triple
interaction, F(4, 56) = 7.87, p < .001. Subsequent simple, simple effects showed that both groups
of rats stepped less with their right forepaw than with their left on all days, Fs(1, 70) > 17.01, ps
< .001, and that L-DOPA increased right forepaw stepping in the saline-injected rats, F(4, 112) =
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43.02, p < .001, and decreased left forepaw stepping in both groups, Fs(4, 112) > 6.52, ps < .001.
Pairwise comparisons indicated that an acute injection of 6 mg/kg L-DOPA (6 LD1) increased
right forepaw stepping in the saline-injected rats compared to the prior saline injection (S10), F(1,
112) = 57.79, p < .001, and that the third injection of 10 mg/kg L-DOPA (10 LD4) further and
asymptotically increased right forepaw stepping, F(1, 112) = 6.80, p < .02, such that right
forepaw stepping increased to the level of that in the ceftriaxone group. L-DOPA had no effect
on right forepaw stepping in the ceftriaxone-injected rats. In contrast, 10 mg/kg L-DOPA
decreased left forepaw stepping in both groups, Fs(1, 112) > 6.57, ps < .02.
50 mg/kg ceftriaxone combined with 10 mg/kg L-DOPA. Daily L-DOPA and ceftriaxone
injections continued as above. In addition, on the 11th day of L-DOPA injections, the saline rats
began receiving daily injections of 50 mg/kg ceftriaxone for 6 days. Testing now occurred every
2 days beginning the day after the first ceftriaxone injection. The Forepaw (2) × Day (the 10th
day of L-DOPA [LD10S21/LD10C21] and three tests with ceftriaxone [LD12C1/LD12C23 –
LD16C5/LD16/C27])× Group (saline, ceftriaxone) ANOVA with repeated measures on forepaw
and day showed only a main effect of forepaw, F(1, 14) = 20.18, p < .001, indicating that adding
ceftriaxone to L-DOPA did not alter stepping in the animals that had previously received only LDOPA injections (the original saline-injected group; see Figure 4). The triple interaction was not
significant, F(3, 42) = 1.91, p < .15, but simple, simple effects tests showed that L-DOPA
progressively decreased left paw stepping in the original saline-injected group, F(3, 84) = 3.70, p
< .02, such that these rats were stepping less with their left paw than were the original
ceftriaxone-injected rats by the 16th day of L-DOPA injections, F(1, 112) = 5.12, p < .03.
Removal of L-DOPA. One day later, the L-DOPA injections were stopped for the original
saline-injected group, while the ceftriaxone injections were continued. The ceftriaxone and L-
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DOPA injections continued as before in the original ceftriaxone-injected group. The data
collected on the second day of L-DOPA removal were compared to those on the preceding 16th
injection of L-DOPA for all rats. The Forepaw (2) × Condition (the 16th day of L-DOPA
[LD16C5/LD16C27], L-DOPA removal [C7/LD18C29]) × Group (saline, ceftriaxone) ANOVA
with repeated measures on forepaw and condition revealed a main effect of forepaw, F(1, 14) =
26.14, p < .001, a Day × Group interaction, F(1, 14) = 8.07, p < .02, and a triple interaction, F(1,
14) = 9.74, p < .01 (see Figure 4). Simple effects tests indicated that right forepaw stepping was
less than left forepaw stepping, Fs(1, 28) > 7.91, ps < .02, except for the original saline-injected
rats on the 16th day of L-DOPA. These simple effects tests also indicated that the removal of LDOPA from the saline-injected rats increased left forepaw stepping, F(1, 28) = 16.13, p < .001.
In contrast, the additional 18th injection of L-DOPA tended to decrease left forepaw stepping in
the original ceftriaxone-injected rats, F(1, 28) = 3.55, p < .08.
DHK and ceftriaxone. Two days later, the original saline-injected rats were given an
injection of 10 mg/kg of the GLT-1 inhibitor DHK in addition to the daily injection of
ceftriaxone, and on the following day were retested without DHK. The Forepaw × Condition
(ceftriaxone [C7], DHK [C9DHK], post-ceftriaxone [PC]) repeated measures ANOVA on the
eight saline rats revealed main effects of forepaw, F(1, 7) = 115.03, p < .001, and condition, F(2,
14) = 84.85, p < .001, and an interaction, F(2, 14) = 23.39, p < .001 (see Figure 4). Simple
effects tests indicated that the rats stepped less with the right forepaw than with their left during
all three tests, Fs(1, 21) > 41.70, ps < .001, and that the drug conditions affected stepping with
both forepaws, Fs(2, 28) > 11.59, ps < .001. Pairwise comparisons indicated that DHK decreased
right forepaw stepping, F(1, 29) = 123.99, p < .001, and that right forepaw stepping increased
back to the level of ceftriaxone alone the following day. In contrast, left forepaw stepping was
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not affected by DHK, but did increase on the following day, F(1, 28) = 19.30, p < .001, back to
the level seen before L-DOPA administration. Although it is possible that the failure to see an
increase in left forepaw stepping during DHK reflected a depressant effect of DHK, I found no
suppression of stepping when 10 mg/kg DHK was subsequently re-administered to two animals
(I ran out of drug) whose left forepaw stepping had returned to pre-L-DOPA baseline by the day
following the initial DHK injection.
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Figure 5. The change in mean total AIM scores (± SEM) during the injections of L-DOPA in
Experiment 2. As in the prior figures, LD = 6 and 10 mg/kg L-DOPA, S = saline, C = ceftriaxone,
and the trailing numbers refer to the day in that condition during which testing occurred. The
symbols to the left of the backslash refer to the original saline-injected group, and the numbers
to the right refer to the original ceftriaxone-injected group.
AIMs
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The Group (L-DOPA combined with ceftriaxone or saline) x Day (8 days of testing [6
LD1/6 LD1C12 – C7/LD19C30]) ANOVA with repeated measures on day revealed a main
effect of day, F(7, 98) = 7.47, p < .001, and an interaction, F(7, 98) = 4.27, p < .001, for total
AIMs. Subsequent simple effects tests showed that AIMs changed across days for both groups,
Fs(7, 98) > 4.00, ps < .001 (see Figure 5). Although 6 mg/kg L-DOPA had no effect, 10 mg/kg
L-DOPA increased AIMS by the first day of testing (LD4) in the saline-injected rats, F(1, 98) =
14.17, p < .001, an increase that was not affected by subsequent injections of L-DOPA or the
addition of ceftriaxone. LID never developed in two of these animals, but the remaining six
consistently averaged 34-40 total AIMs from LD10 on. Total AIMs returned to zero in all saline
rats on the day following discontinuation of L-DOPA (C7).
In contrast, 10 mg/kg L-DOPA did not significantly increase total AIMS in the
ceftriaxone-injected rats until the fourth day of testing (LD10), F(1, 98) = 4.42, p < .05. These
AIMs reached a peak on the fifth and sixth days of testing (LD12 and 14), Fs(1, 98) = 5.03, ps
< .05, decreased to insignificance on the seventh day of testing (LD16), and were restored by the
last day of testing (LD18), F(1, 98) = 12.00, p < .001. Only six of the eight animals developed
AIMS, and only one expressed more than 35 total AIMS consistently. Among these six rats,
there were 15 days on which total AIMs was less than 6, whereas there was only 1 such day in
the saline-injected rats. Further indicating that subchronic ceftriaxone reduced the development
of LID, simple effects tests showed that the ceftriaxone group expressed fewer total AIMs than
the saline group on LD10, F(1, 112) = 4.03, p = .05, and LD16, F(1, 112) = 4.59, p < .02.
Body weight. The body weight data for the testing days are shown in Figure 6. The Group
(2) × Day (15) ANOVA with repeated measures on day revealed only a main effect of day, F(1,
14) = 49.47, p < .001 (see Figure 6). Although it appears as though injections of ceftriaxone
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slowed the increase in body weight initially in the ceftriaxone-treated rats and later in the saline
rats, these effects were not significant.
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Figure 6. The change in mean body weight (± SEM) in gm over the course of the experiment. As
in Figures 4 and 5, the letters on the x-axis refer to the drug condition (B = baseline; C = 50
mg/kg ceftriaxone; LD = 6 and 10 mg/kg L-DOPA; DHK = 10 mg/kg DHK), and the trailing
numbers refer to the day in that condition during which testing occurred. The symbols to the
left of the backslash refer to the original saline-injected group, and the numbers to the right
refer to the original ceftriaxone-injected group.
Discussion
Unilateral 6-OHDA lesions
As in Experiment 1, the unilateral MFB lesions decreased right forepaw stepping by 80%
in the eight saline-injected animals and by 81% in the ceftriaxone-injected rats, presumably
reflective of approximately 80% depletion of DA in the contralateral striatum (Chang et al.,
1999).
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50 mg/kg ceftriaxone
The first acute injection of 50 mg/kg ceftriaxone improved impaired right forepaw
stepping by 19% when tested within 45 min of the injection, an effect that is remarkably similar
to the increase seen in Experiment 1 when the effects of an acute injection of 100 mg/kg
ceftriaxone was tested on stepping that had not yet returned to baseline following ceftriaxone
removal. Both effects are likely caused by an increase in GLT-1 function rather than expression,
as GLT-1 expression takes more time to occur (Chu et al., 2007; Lipski et al., 2007). Subsequent
injections further increased, but did not normalize, stepping, which appeared to reach asymptote
(41% improvement compared to baseline) after the sixth injection. The exceptional similarity in
the time course and magnitude of effects of 50 mg/kg ceftriaxone in this experiment and 100
mg/kg in Experiment 1 is somewhat surprising as other experiments have shown that 100 mg/kg
has a larger effect on behavior, GLT-1 expression, and glutamate clearance (Rasmussen et al.,
2011; Sari et al., 2009). This suggests that in the 6-OHDA model of PD, where there is no
ongoing neurodegeneration, only a moderate upregulation in GLT-1 is required to improve
symptoms. Given that 50 mg/kg ceftriaxone appears to be sufficient in this model, it is
interesting to note that 100 mg/kg and the presumed excess GLT-1 does not cause any noticeable
side effects, as are typically seen with higher doses of L-DOPA and NMDA antagonists (Chu et
al., 2007). This finding and others would seem to make ceftriaxone an ideal alternative to
NMDA antagonists that have low therapeutic indexes (Bibbiani et al., 2005; Metman et al.,
1998).
L-DOPA With and Without Ceftriaxone
An acute injection of 6 mg/kg L-DOPA caused a 30% increase in right forepaw stepping
in the previously saline-injected group, somewhat larger than the 18% improvement seen in
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Experiment 1. Subsequent injections of 10 mg/kg L-DOPA caused a significantly larger 48%
increase in stepping, bringing stepping to the level produced by 50 mg/kg ceftriaxone. This LDOPA-induced increase in right forepaw stepping was expected, as previous research has shown
similar results (Chang et al., 1999; Kelsey et al., 2004). As in Experiment 1, there was, however,
no additive effect of L-DOPA, at either dose, on right forepaw stepping in the rats receiving
ceftriaxone, which may be due to a ceiling effect on impairment (Kelsey et al., 2004; Kelsey et
al., 2009).
In contrast to ceftriaxone, the addition of 10 mg/kg L-DOPA caused a significant
decrease in left forepaw stepping, an effect that increased with repeated injections, and is most
likely due to the development of LID (see below). This effect is often seen when the dyskinetic
movements in the unimpaired limb interfere with stepping, as shown previously in our lab (Chen,
2009). The fact that ceftriaxone is as good as a highly therapeutic dose of L-DOPA at improving
stepping but does not affect the unimpaired forepaw further indicates that ceftriaxone may prove
to be a better treatment for the motor impairments associated with L-DOPA.
Just as the addition of L-DOPA did not alter the effects of ceftriaxone on right forepaw
stepping, the addition of ceftriaxone did not alter the effects of L-DOPA on right forepaw
stepping. Nor did it stop the progressive decrease in left forepaw stepping produced by L-DOPA
in the previously saline-injected rats. However, the finding that left forepaw stepping was less
impaired in the original ceftriaxone group, indicates that prior treatment with ceftriaxone may
slow the development of this impairment, a point that will be elaborated on in the section on
AIMs. Not surprisingly, left forepaw stepping significantly improved within 24 hr of the
cessation of L-DOPA injections in the original saline group. The finding that left forepaw
stepping did not fully return to pre-L-DOPA levels immediately suggests that L-DOPA caused

47
some lasting effects. Because the DA receptors become highly sensitized during LID (Darmopil
et al., 2009), it is likely that this sensitization remains for some time after cessation of L-DOPA
treatment.
DHK
Acute treatment of the rats still on ceftriaxone with 10 mg/kg dihydrokainate (DHK), a
selective GLT-1 blocker, caused a significant reduction in the ameliorative effects of ceftriaxone
on right forepaw stepping, without affecting left forepaw stepping. Although this dose did not
eliminate the effects of ceftriaxone, it does indicate that at least the bulk of the effects of
ceftriaxone on forepaw stepping are, as I have suggested, due to increased GLT-function. In the
absence of direct measures of GLT-1 mRNA and protein and glutamate clearance before and
after DHK administration, we can’t be certain precisely where the effects lie.
AIMs
Daily injections of 10 mg/kg L-DOPA caused the development of LID by the fourth day
of treatment in rats given saline, at which point AIMs had seemingly reached an asymptote. This
procedure has become rather standard for producing LID in this animal model (Cenci & Ohlin,
2009; Lundblad, Anderson, Winkler, Kirik, Wierup, & Cenci, 2002), and my results are similar.
It is of interest to note that two of the eight animals were resistant to the development of LID,
while the other six consistently expressed almost maximal AIMs. The subsequent addition of 50
mg/kg ceftriaxone did not decrease the expression of AIMs. This is apparently contradictory to
findings of Miller et al. (2008), who found a decrease in HD-associated paw clasping, which is
similar to dyskinesia, after ceftriaxone treatment. However, they used 200 mg/kg ceftriaxone,
suggesting that ceftriaxone may be able to decrease the expression of AIMs at higher doses.
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Nevertheless, pretreatment with ceftriaxone did slow the development of LID and the
associated impairment in left forepaw stepping in the ceftriaxone group. Additionally, although
six of the eight rats in this group did eventually express as much LID as the rats in the saline
group, they did so far less consistently. These findings suggest that the reduction of glutamate
transmission produced by ceftriaxone may reduce the sensitization of the NMDA and AMPA
receptors typically seen in LID, but are unable to reverse this sensitization once it has developed
(at least at the dose I used) (Bagetta et al., 2010; Kobylecki et al., 2010; Oh et al., 1998).
Body Weight
Although none of these effects were statistically significant, the initial injections of 50
mg/kg ceftriaxone caused a minor suppression of weight gain in both groups that was transient.
This observation is consistent with the findings in Experiment 1 that ceftriaxone is able to
suppress weight gain. However, the suppression appears to be longer lasting in the previous
experiment, most likely due to the larger dose (100 mg/kg) of ceftriaxone. The observation that
ceftriaxone appears to slow weight gain is an important consideration if ceftriaxone is to be used
for a prolonged period in people for the treatment of any disease. However, this small effect was
the only negative side noted in either experiment, demonstrating the almost complete lack of side
effects of ceftriaxone.
General Discussion
As of yet, there is no way to prevent or even slow the progressive neurodegeneration of
Parkinson’s disease. The only therapies that exist focus on symptom management. The most
effective drug for decreasing the motor symptoms of PD is the dopamine precursor L-DOPA
which acts to increase DA synthesis, and thus transmission, in the dopamine-depleted striatum.
However, after a few years of L-DOPA therapy, the therapeutic effects of L-DOPA decline, and
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the majority of patients develop L-DOPA-induced dyskinesia as a side effect. Based on data that
one of the key problems behind PD and LID pathology is increased glutamate transmission
(Calabresi et al., 1993; Chung et al., 2008; Lievens et al., 2001; Nash & Brotchie, 2002), I
hypothesized that the upregulation of the primary glutamate transporter GLT-1, known to
decrease extracellular glutamate, by ceftriaxone might be beneficial to the treatment of the motor
symptoms associated with both PD and LID.
The data from my experiments show that repeated injections of both 50 and 100 mg/kg
ceftriaxone are as effective as 10 mg/kg L-DOPA at improving impaired forepaw stepping in the
6-OHDA-lesioned hemi-Parkinsonian rat, and, in contrast to L-DOPA, produce no detectable
dyskinesia. Also in contrast to L-DOPA, the effects of ceftriaxone are long-lasting and are still
apparent even 30 days after the termination of ceftriaxone. Given that ceftriaxone has been
proven safe in humans, it would appear as though it would offer several substantial advantages
over traditional L-DOPA therapy. Although the data strongly support the use of ceftriaxone as
monotherapy, it is possible that ceftriaxone could be useful as adjunctive therapy. While
ceftriaxone does not reduce the expression of already established LID, it does reduce the
development. Because the doses of each produced maximal therapeutic effects, I was unable to
determine if subthreshold doses of both would produce additive effects and reduce the
development of LID even further.
By blocking GLT-1 function with DHK, I was able to show that the therapeutic effects of
ceftriaxone on forepaw stepping were due, at least in large part, to ceftriaxone’s action on GLT-1.
Given that ceftriaxone had therapeutic effects acutely and at a dose (50 mg/kg) that has not been
shown to upregulate GLT-1 expression (Chu et al., 2007), it is likely that at least some of these
effects are due to an ability of ceftriaxone to increase the activity of GLT-1.
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Limitations
The biggest limitation of this study was the inability to determine the exact mechanism
by which ceftriaxone acts to improve the motor deficits of Parkinson’s disease. Because the
effects of ceftriaxone were not completely eliminated by DHK, mechanisms other than enhanced
GLT-1 activity are possible. Additionally, the injection of DHK did not determine exactly how
ceftriaxone acted on GLT-1, and there is no one clear answer to be found in the literature.
Although these data would not have been decisive, this study would have benefited from a
determination of GLT-1 mRNA and protein expression and especially from measures of
extracellular glutamate uptake and concentration. It would also be interesting to examine
ceftriaxone’s effects on other physiological changes typically associated with PD and LID such
as striatal enkephalin and dynorphin levels and D1 and D2 receptor function.
The study of ceftriaxone’s effects on LID was limited by the expense of ceftriaxone. I
would have liked to determine if a higher dose (200 mg/kg) used to improve the motor symptoms
of Huntington’s disease would have decreased LID expression. Because 50 mg/kg slows LID
development, it seems possible that higher doses of ceftriaxone might reduce LID expression.
Future Directions
There are a number of additional studies that could clarify or enhance the results found in
this study. As discussed in the introduction, the mechanism of ceftriaxone action is not well
understood. Although it is thought that ceftriaxone acts to decrease glutamate through GLT-1, it
is not clear if this is mediated through an increase in protein expression and/or function. The
results of this study suggest that ceftriaxone acts acutely by increasing GLT-1 function, but less
is known about the effects of multiple doses. The finding that DHK did not completely reverse
the effects of ceftriaxone raise the possibility that ceftriaxone may not act completely through
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GLT-1 modification in this model. Thus, it would be of value to determine if larger doses of
DHK would produce a more complete blockade, and it would be extremely useful to determine if
these effects can be blocked by injections of DHK into various locations within the basal ganglia
as that is the presumed site of GLT-1 modification.
The long lasting effects of ceftriaxone in this and other studies, consistent with an
upregulation of a protein, suggest that ceftriaxone would not need to be injected every day and
that the therapeutic effects of ceftriaxone could be achieved with far less frequent injections.
This implication should be tested, and, if confirmed, would provide yet another advantage over
L-DOPA, which must be taken daily. Fewer administrations would also be useful, as ceftriaxone
is only currently available to humans as an IV injection (Nau et al., 1993).
Although it seems unlikely that ceftriaxone is effective in this study because it has
decreased ongoing neurodegeneration, the fact that it can reduce such degeneration in animal
models of other disorders (Rothstein et al., 2005) suggests that it is possible that ceftriaxone
could also reduce ongoing degeneration in PD. Thus, it is possible that ceftriaxone could reduce
the progression or perhaps even prevent the occurrence of PD in addition to ameliorating the
symptoms. Consequently, it would be useful to determine if pretreatment with ceftriaxone would
reduce the degeneration and behavioral effects of 6-OHDA injections in our model or in the
MPTP-treated mouse model, as MPTP appears to produce a more sustained degeneration.
Because of ceftriaxone’s success in animal models of ALS, it is now being tested in stage
III clinical trials for this disorder (Traynor et al., 2006). Because of the lack of side effects when
used to treat meningitis at similar doses (Nau et al., 1993), its efficacy in neurodegenerative
studies (Rothstein et al., 2005; Thone-Reinke et al., 2008), and the behavioral effects found in
this study, it seems likely that ceftriaxone may be a good candidate for clinical trials in
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Parkinson’s disease to both treat the motor symptoms more effectively than L-DOPA and
perhaps even reduce degeneration. On a more modest level, it certainly seems that ceftriaxone
could be a viable alternative to NMDA antagonists which, although efficacious at reducing LID
in human patients (Snow et al., 2000), have a number of undesirable cognitive side effects
(Caraci et al., 2012).
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